ArticleBlood advances2018
Prognostic impact of low allelic ratio
Open access · goldAbstract read
In one paragraph
Article in Blood advances, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers.
0numbers the graph read from it
0cells of the map it votes in
73citing papers in PubMed
10.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
73 citing papers in PubMed, 128 citations in OpenAlex.
- Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib.Blood advances · 2022Trial
- Allogeneic hematopoietic stem cell transplantation at the first remission for younger adults with FLT3-internal tandem duplication AML: The JALSG AML209-FLT3-SCT study.Cancer science · 2020Trial
- FLT3-Mutated AML: Transplanting with Precision in the Targeted Era.Current hematologic malignancy reports · 2026Review
- Review
- IHCH9033, a novel class I HDAC inhibitor, synergizes with FLT3 inhibitor and rescues quizartinib resistance in FLT3-ITD AML via enhancing DNA damage response.Experimental hematology & oncology · 2025Article
- Advancements in leukemia management: Bridging diagnosis, prognosis and nanotechnology (Review).International journal of oncology · 2024Review
- Co-mutation landscape and its prognostic impact on newly diagnosed adult patients with NPM1-mutated de novo acute myeloid leukemia.Blood cancer journal · 2024Article
- Validation of the 2022 European LeukemiaNet risk stratification for acute myeloid leukemia.Scientific reports · 2024Article
- Next-generation sequencing reveals relapse and leukemia-free survival risks in newly diagnosed acute myeloid leukemia treated with CAG regimen combined with decitabine.Cancer pathogenesis and therapy · 2024Article
- The Clinical Utility ofCurrent oncology (Toronto, Ont.) · 2023Article
- What Influences the Decision to Proceed to Transplant for Patients With AML in First Remission?Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Review
- Genetic Polymorphism Study of IDH 1/2 and TET2 Genes in Acute Myeloid leukemia Patients.Asian Pacific journal of cancer prevention : APJCP · 2023Article
- Overcoming relapse: prophylactic or pre-emptive use of azacitidine or FLT3 inhibitors after allogeneic transplantation for AML or MDS.International journal of hematology · 2023Review
- Shift of N-MYC Oncogene Expression in AML Patients Carrying the FLT3-ITD Mutation.Pathophysiology : the official journal of the International Society for Pathophysiology · 2023Article
- Prognostic impact of FLT3-ITD, NPM1 mutation and CEBPA bZIP domain mutation in cytogenetically normal acute myeloid leukemia: a Hokkaido Leukemia Net study.International journal of hematology · 2023Article
- Ultrasensitive quantitation of FLT3-ITD mutation in patients with acute myeloid leukemia using ddPCR.Molecular biology reports · 2023Article
- Review
- Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia.Leukemia · 2023Article
- Mutational analysis of DNMT3A improves the prognostic stratification of patients with acute myeloid leukemia.Cancer science · 2023Article
- [Clinical study of induction chemotherapy followed by allogeneic hematopoietic stem cell transplantation in the treatment of FLT3-ITD(+) acute myeloid leukemia with normal karyotype].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2023Article
13 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
36 authors at 16 institutions in 1 country.
Masahiro SakaguchiDepartment of Hematology, Nippon Medical School, Tokyo, Japan.
Hiroki YamaguchiDepartment of Hematology, Nippon Medical School, Tokyo, Japan.
Yuho NajimaDivision of Hematology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
Kensuke UsukiDepartment of Hematology, NTT Medical Center Tokyo, Tokyo, Japan.
Toshimitsu UekiDepartment of Hematology, Nagano Red Cross Hospital, Nagano, Japan.
Iekuni OhDivision of Hematology, Department of Medicine, Jichi Medical University, Tochigi, Japan.
Sinichiro MoriHemato-Oncology Department, St Luke's International Hospital, Tokyo, Japan.
Eri KawataDepartment of Hematology, Japanese Red Cross Kyoto Daini Hospital, Kyoto, Japan.
Nobuhiko UoshimaDepartment of Hematology, Japanese Red Cross Kyoto Daini Hospital, Kyoto, Japan.
Yutaka KobayashiDepartment of Hematology, Japanese Red Cross Kyoto Daini Hospital, Kyoto, Japan.
Shinichi KakoDivision of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.
Kenji TajikaDepartment of Hematology, Yokohama Minami Kyousai Hospital, Kanagawa, Japan.
Seiji GomiDepartment of Hematology, Yokohama Minami Kyousai Hospital, Kanagawa, Japan.
Katsuhiro ShonoDepartment of Hematology, Chiba Aoba Municipal Hospital, Chiba, Japan.
Kensuke KayamoriDepartment of Hematology, Chiba University Hospital, Chiba, Japan.
Masao HagiharaDepartment of Hematology, Eiju General Hopital, Tokyo, Japan.
Junya KandaDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Hitoji UchiyamaDepartment of Hematology, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan.
Junya KurodaDivision of Hematology and Oncology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Naoyuki UchidaDepartment of Hematology, Federation of National Public Service Personnel Mutual Aid Associations, Toranomon Hospital, Tokyo, Japan.
Yasushi KubotaDivision of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan; and.
Shinya KimuraDivision of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan; and.
Saiko KurosawaDepartment of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
Nana NakajimaDepartment of Hematology, Nippon Medical School, Tokyo, Japan.
Atsushi MarumoDepartment of Hematology, Nippon Medical School, Tokyo, Japan.
Ikuko OmoriDepartment of Hematology, Nippon Medical School, Tokyo, Japan.
Yusuke FujiwaraDepartment of Hematology, Nippon Medical School, Tokyo, Japan.
Shunsuke YuiDepartment of Hematology, Nippon Medical School, Tokyo, Japan.
Satoshi WakitaDepartment of Hematology, Nippon Medical School, Tokyo, Japan.
Kunihito AraiDepartment of Hematology, Nippon Medical School, Tokyo, Japan.
Tomoaki KitanoDepartment of Hematology, Nippon Medical School, Tokyo, Japan.
Kazuhiko KakihanaDivision of Hematology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.ORCID 0000-0001-5062-5795
Yoshinobu KandaDivision of Hematology, Department of Medicine, Jichi Medical University, Tochigi, Japan.
Kazuteru OhashiDivision of Hematology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
Takahiro FukudaDepartment of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
Koiti InokuchiDepartment of Hematology, Nippon Medical School, Tokyo, Japan.
Nippon Medical School · JPJapanese Red Cross Society Kyoto Daini Hospital · JPJichi Medical University · JPTokyo Metropolitan Komagome Hospital · JPSaga University · JPYokohama Minami Kyosai Hospital · JPChiba Aoba Municipal Hospital · JPChiba University Hospital · JPEiju General Hospital · JPKyoto first Red Cross hospital · JPKyoto Prefectural University of Medicine · JPKyoto University · JPNagano Red Cross Hospital · JPNTT Medical Center · JPSt. Luke's International Hospital · JPToranomon Hospital · JP
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the opinion of the European LeukemiaNet (ELN), nucleophosmin member 1 gene mutation (
Indexed as
AdolescentAdultAgedAged, 80 and overFemalefms-Like Tyrosine Kinase 3HumansLeukemia, Myeloid, AcuteMaleMiddle AgedMutationNuclear ProteinsNucleophosminPrognosisRetrospective StudiesYoung Adultfms-Like Tyrosine Kinase 3NPM1 protein, humanNuclear ProteinsNucleophosmin
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.